AwesomeCapital

Search This Blog

Wednesday, September 25, 2019

Portable electronics: A stretchable and flexible biofuel cell that runs on sweat

A unique new flexible and stretchable device, worn against the skin and capable of producing electrical energy by transforming the compounds present in sweat, was recently developed and patented by CNRS researchers from l’Université Grenoble Alpes and the University of San Diego (USA). This cell is already capable of continuously lighting an LED, opening new avenues for the development of wearable electronics powered by autonomous and environmentally friendly biodevices. This research was published in Advanced Functional Materials on September 25, 2019.
The potential uses for wearable electronic devices continue to increase, especially for medical and athletic monitoring. Such devices require the development of a reliable and efficient energy source that can easily be integrated into the human body. Using “biofuels” present in human organic liquids has long been a promising avenue.
Scientists from the Département de chimie moléculaire (CNRS/Université Grenoble Alpes), who specialize in bioelectrochemistry, decided to collaborate with an American team from the University of San Diego in California, who are experts in nanomachines, biosensors, and nanobioelectronics. Together they developed a flexible conductive material consisting of carbon nanotubes, crosslinked polymers, and enzymes joined by stretchable connectors that are directly printed onto the material through screen-printing.
The biofuel cell, which follows deformations in the skin, produces electrical energy through the reduction of oxygen and the oxidation of the lactate present in perspiration. Once applied to the arm, it uses a voltage booster to continuously power an LED. It is relatively simple and inexpensive to produce, with the primary cost being the production of the enzymes that transform the compounds found in sweat. The researchers are now seeking to amplify the voltage provided by the biofuel cell in order to power larger portable devices.
Patents:
F. Giroud, A. J. Gross, S. Cosnier. Bioelectrode for the detection and/or oxidation of glucose and its manufacturing process and device comprising it. French patent n° 1662997 submitted December 21, 2016 . Published 22 June 2018. Extension PCT n°PCT/FR2017053689 submitted December 21, 2017. Published PCT n° WO2018115710A1 28 June 2018.. Applicants: CNRS
S. Cosnier, R. Haddad. Electrochemical reactor block. French patent n° 1559069 submitted September 25, 2015 ; n°3041819. Published March 31, 2017. Extension Europe, USA, Japan n°16777723.4 ; FR20160552310 ; submitted September 14, 2016.. Applicants: Université Joseph Fourier and CNRS
make a difference: sponsored opportunity

Story Source:
Materials provided by CNRS. Note: Content may be edited for style and length.

Journal Reference:
  1. Xiaohong Chen, Lu Yin, Jian Lv, Andrew J. Gross, Minh Le, Nathaniel Georg Gutierrez, Yang Li, Itthipon Jeerapan, Fabien Giroud, Anastasiia Berezovska, Rachel K. O’Reilly, Sheng Xu, Serge Cosnier, and Joseph Wang. Stretchable and Flexible Buckypaper-Based Lactate Biofuel Cell for Wearable Electronics. Advanced Functional Materials, 2019 DOI: 10.1002/adfm.201905785
https://www.sciencedaily.com/releases/2019/09/190925123431.htm
Posted by AwesomeCapital at 11:47 PM
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Newer Post Older Post Home
Subscribe to: Post Comments (Atom)

Blog Archive

  • ►  2026 (1417)
    • ►  January (1417)
  • ►  2025 (20273)
    • ►  December (1706)
    • ►  November (1621)
    • ►  October (1859)
    • ►  September (1690)
    • ►  August (1714)
    • ►  July (1681)
    • ►  June (1631)
    • ►  May (1558)
    • ►  April (1590)
    • ►  March (1900)
    • ►  February (1547)
    • ►  January (1776)
  • ►  2024 (17567)
    • ►  December (1320)
    • ►  November (1464)
    • ►  October (1549)
    • ►  September (1529)
    • ►  August (1674)
    • ►  July (1415)
    • ►  June (1247)
    • ►  May (1442)
    • ►  April (1409)
    • ►  March (1422)
    • ►  February (1406)
    • ►  January (1690)
  • ►  2023 (17794)
    • ►  December (1359)
    • ►  November (1422)
    • ►  October (1490)
    • ►  September (1167)
    • ►  August (1472)
    • ►  July (1639)
    • ►  June (1628)
    • ►  May (1654)
    • ►  April (1632)
    • ►  March (1284)
    • ►  February (1632)
    • ►  January (1415)
  • ►  2022 (14151)
    • ►  December (1397)
    • ►  November (1235)
    • ►  October (1311)
    • ►  September (1135)
    • ►  August (1066)
    • ►  July (1047)
    • ►  June (1022)
    • ►  May (1196)
    • ►  April (1190)
    • ►  March (1236)
    • ►  February (1054)
    • ►  January (1262)
  • ►  2021 (11137)
    • ►  December (1167)
    • ►  November (958)
    • ►  October (643)
    • ►  September (775)
    • ►  August (884)
    • ►  July (919)
    • ►  June (871)
    • ►  May (975)
    • ►  April (1061)
    • ►  March (1038)
    • ►  February (881)
    • ►  January (965)
  • ►  2020 (12053)
    • ►  December (902)
    • ►  November (768)
    • ►  October (872)
    • ►  September (806)
    • ►  August (854)
    • ►  July (980)
    • ►  June (1046)
    • ►  May (1218)
    • ►  April (1258)
    • ►  March (1293)
    • ►  February (1041)
    • ►  January (1015)
  • ▼  2019 (14242)
    • ►  December (897)
    • ►  November (1053)
    • ►  October (1052)
    • ▼  September (898)
      • Spending Variation ‘Substantial’ Between Providers...
      • Servier acquires lymphoma treatment PIXUVRI from C...
      • AstraZeneca Update on US regulatory review of PT01...
      • Three pharmacies now pulling Zantac over FDA alert
      • Bristol-Myers Squibb (BMY) Presents At ESMO Congre...
      • Dementia Outcomes Improved With Supportive Care
      • Cancer immunotherapy boom showing no sign of slowdown
      • What’s in your CBD? Buyer beware
      • FDA issues warning letters to websites selling ill...
      • AnaptysBio -13.5% after GALLOP trial data
      • Biotech Investors: Mark Your Calendar For These Oc...
      • Drugmakers Eye Purdue Pharma’s Bankruptcy to Settl...
      • NewLink -1.3% on Lumos merger
      • Catabasis Pharmaceuticals moves forward on Polaris...
      • Geron +12.7% on fast-track designation
      • Possible therapeutic target for slow healing of ag...
      • Esmo 2019 – mesothelioma trials contend with super...
      • Vir Biotech files for IPO to raise ~$134M
      • Bristol-Myers higher after Opdivo update
      • Pfizer eyes commercial scale-up as Array colorecta...
      • What Do the J&J and Purdue Pharma Outcomes Mean to...
      • Dana-Farber Study Confirms Accuracy of GRAIL’s Blo...
      • Zymeworks upped to Strong Buy by Raymond Jame
      • Unitedhealth cut to Market Perform by BMO
      • Humana cut to Market Perform by BMO
      • Cigna upped to Outperform by BMO
      • Bellus started at Buy by Jefferies
      • Adamas cut to Underperform by B of A
      • Lexicon Pharma -13.8% as Mako warns of deal breaku...
      • AstraZeneca, Merck’s Lynparza meets primary goal i...
      • Pfizer reports positive data from late-stage BEACO...
      • Amgen off after early stage AMG 510 data disappoints
      • Genentech to present positive Tecentriq data
      • Aquestive completes early-stage AQST-108 trial
      • Moderna announces open IND for Propionic Acidemia ...
      • Endo International rises 2.2% after litigation mat...
      • Mallinckrodt +13% after settling Ohio opioid cases
      • FDA OKs Turning Point’s IND for TPX-0046
      • Acasti Pharma updates on Trilogy 1 and 2 trials
      • FDA clears expanded label for Crysvita
      • Dova Pharma to be acquired by Sobi
      • Trovagene reports positive mid-stage data from Onv...
      • Atossa Genetics reports positive Endoxifen data
      • Johnson & Johnson discloses positive Invokana deve...
      • Humana, UNH downgraded on Medicare Advantage risk
      • Trump to give health care speech in Florida this week
      • Nasdaq cracks down on IPOs of small Chinese companies
      • Biotech week ahead, Sept. 30
      • Seattle Genetics Initial Results in Metastatic Col...
      • Calithera, Incyte present initial Phase 1 colorect...
      • Merck Keytruda Plus Chemo Ups Response V. Chemo in...
      • Lilly Announces Positive Registrational Data for T...
      • Vape concerns weigh on Canada cannabis companies l...
      • Clovis Updates Data from Prostate, Ovarian Cancer ...
      • ImmunoGen at ESMO: Full Data from Phase 3 Trial in...
      • Healthcare Could Become Bigger For Best Buy Than S...
      • Vaping Hoodies? Parents And Teachers Continue To B...
      • Why Are Young People Getting Type 2 Diabetes In Di...
      • Democrats Are Retreating on Single Payer Health Care
      • There aren’t enough doctors for Medicare for all
      • The whys of 15 latest hospital closures
      • Hospitals and insurers question legality, need for...
      • Amgen update from ESMO, Sept. 28, 2019
      • IPO Week Ahead: A wave of biotechs and billion-dol...
      • CVS Suspends Sales of Zantac and Other Ranitidine ...
      • Immunomedics Interim Trial Results, Corporate Upda...
      • Glaxo Says Ovarian Cancer Study Validates Tesaro A...
      • AstraZeneca’s Lynparza Yields Positive Study Results
      • Aileron Interim Data for ALRN-6924 Combo with Pfiz...
      • ESSA New Data on EPI-7386 at ESMO 2019
      • Gene-editing Beam Therapeutics sets sights on $100...
      • ESMO: G1 shares data on significant increase in br...
      • Low response rate reported for Amgen targeted drug...
      • Glaxo updates anti-tumour activity with GSK3359609...
      • Bicycle Therapeutics Updates Phase I/IIa Trial in ...
      • Roche data at ESMO 2019 on first-line med for non-...
      • Amgen New Data on KRAS(G12C) Inhibitor In Solid Tu...
      • Seattle Genetics, Astellas Announce Phase 1 Bladde...
      • Most vaping-related lung injuries linked to mariju...
      • Treating C. difficile infections: New purpose for ...
      • A model for brain activity during brain stimulatio...
      • Math models of flu transmission rates indicate uni...
      • Nearly 1 in 3 patients with lupus use prescription...
      • Harmful metals found in vapors from tank-style ele...
      • Walmart offers near-free college tuition to employ...
      • Intercept Pharma files U.S. application for obetic...
      • FTC makes 2nd request for information related to A...
      • Common nutrient supplementation may hold answers t...
      • Study Raises Questions About Universal Screening f...
      • 23andMe moves past consumer DNA tests to clinical ...
      • U.S. alerts travelers to Tanzania about possible u...
      • Change introduced in the CRISPR babies experiment ...
      • CDC, officials tie vaping-related illnesses to ‘Da...
      • Citron bearish on McKesson, shares down
      • ElectroCore continues FDA-stoked selloff
      • Hospitals profit more from doctor-administered med...
      • FDA OKs Roche's Rituxan for rare blood vessel infl...
      • GoodRx acquires telemedicine firm HeyDoctor to add...
      • Osteoporosis: substantial medical and economic bur...
      • CDC recommends against using vapes with marijuana ...
    • ►  August (1149)
    • ►  July (1154)
    • ►  June (1070)
    • ►  May (1349)
    • ►  April (1303)
    • ►  March (1220)
    • ►  February (1497)
    • ►  January (1600)
  • ►  2018 (9593)
    • ►  December (1246)
    • ►  November (1211)
    • ►  October (1284)
    • ►  September (1206)
    • ►  August (1337)
    • ►  July (1092)
    • ►  June (1237)
    • ►  May (956)
    • ►  April (24)
Simple theme. Powered by Blogger.